Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma-Reference-Cited by-同舟云学术

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Published:2019-01-14 Issue:1 Volume:19 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Bahig Houda,Aubin Francine,Stagg John,Gologan Olguta,Ballivy Olivier,Bissada Eric,Nguyen-Tan Felix-Phuc,Soulières Denis,Guertin Louis,Filion Edith,Christopoulos Apostolos,Lambert Louise,Tehfe Mustapha,Ayad Tareck,Charpentier Danielle,Jamal Rahima,Wong Philip^ORCID

Funder

AstraZeneca Canada Inc.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-019-5266-4.pdf

Reference60 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

2. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer. 1993;71(2):452–6.

3. Ferlito A, Shaha AR, Silver CE, Rinaldo A, Mondin V. Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63(4):202–7.